Atrix Laboratories announced that it seeks marketing approval from the Food and Drug Administration for its Atridox drug product for the treatment of periodontal disease.
- The company submitted a New Drug Application to the FDA April 1.
- A spokesperson for the company said Atridox is a non-invasive therapy that is faster and less painful than mechanical scaling and root planing.
- Pending regulatory approval, the Atridox product will be marketed in North America and certain European countries by Block Drug Co.
- For more information, contact Atrix Laboratories, Inc., 2579 Midpoint Drive, Fort Collins, CO 80525; www.atrixlabs.com.
